Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors

Pfizer

Status and phase: Completed; Phase 1

Conditions: Carcinoma

Treatments: Drug: Axitinib (AG-013736)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00447005

A4061022

Details and patient eligibility

About

To evaluate the clinically recommended dose of AG-013736 (Axitinib) in Japanese patients by reviewing the safety of AG-013736 (Axitinib) following single and multiple dosing.

Enrollment: 12 patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients histologically or cytologically diagnosed with advanced malignant solid tumors
• Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies

Exclusion criteria

• Central lung lesions involving major blood vessels
• Patients who have been treated with bevacizumab or other VEGFR inhibitor(s)

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

Open

Experimental group

Treatment:

Drug: Axitinib (AG-013736)